Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTY4KN)

• Drug Name: Dexefaroxan Drug Info
• Synonyms: Dexefaroxan [INN]; (+)-(r)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline; 2-[(2R)-2-ethyl-3H-1-benzofuran-2-yl]-4,5-dihydro-1H-imidazole

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Phase 2	[1]
Schizophrenia	6A20	Discontinued in Phase 2	[2]

• Cross-matching ID:
  PubChem CID: 208820
  CAS Number: CAS 143249-88-1
  TTD Drug ID: DMTY4KN

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosine A2a receptor (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Allergic rhinitis	CA08.0	Approved	[3]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[4]
Regadenoson	DM76VHG	Radionuclide imaging	N.A.	Approved	[5]
Tozadenant	DMATC14	Parkinson disease	8A00.0	Phase 3	[6]
Binodenoson	DMVHF8G	Hypertension	BA00-BA04	Phase 3	[7]
Apadenoson	DMD8QTC	Coronary artery disease	BA80	Phase 3	[8]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[9]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[10]
BIIB014	DMH7RJ1	Parkinson disease	8A00.0	Phase 2	[11]
MRE-0094	DMQR23W	Diabetic foot ulcer	BD54	Phase 2	[12]

Drug(s) Targeting Nicotinic acetylcholine receptor (nAChR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[13]
Cotinine	DMCEZ1B	Insecticide	N.A.	Approved	[14]
Pancuronium	DMB0VY8	Anaesthesia	9A78.6	Approved	[15]
Atracurium	DM42HXN	Anaesthesia	9A78.6	Approved	[15]
Mecamylamine	DMGQFYB	Essential hypertension	BA00	Approved	[16]
CYTISINE	DMUF0BJ	Tobacco dependence	6C4A.2	Phase 3	[17]
BMS-954561	DM7XV4R	Diabetic neuropathy	8C0Z	Phase 2	[18]
ASM-024	DM35S2I	Asthma	CA23	Phase 2	[19]
NIC-002	DMKLJMI	Nicotine dependence	6C4A.2	Phase 2	[20]
TRIDMAC	DMWU41P	Mood disorder	6A60-6E23	Phase 2	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Agonist	[2]
Nicotinic acetylcholine receptor (nAChR)	TTJSZTB	NOUNIPROTAC	Agonist	[2]

References

• [1] Effects of the alpha 2-adrenoreceptor antagonist dexefaroxan on neurogenesis in the olfactory bulb of the adult rat in vivo: selective protection against neuronal death. Neuroscience. 2003;117(2):281-91.
• [2] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [3] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [6] Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
• [7] Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
• [9] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [10] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [11] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
• [12] Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.
• [13] Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors. Neuropharmacology. 2009 Aug;57(2):183-91.
• [14] Functional versus chemical diversity: is biodiversity important for drug discovery. Trends Pharmacol Sci. 2002 May;23(5):225-31.
• [15] Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52.
• [16] Mecamylamine (Inversine): an old antihypertensive with new research directions. J Hum Hypertens. 2002 Jul;16(7):453-7.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] EP patent application no. 2774991, Drug delivery system for use in the treatment or diagnosis of neurological disorders.
• [19] Effects of ASM-024, a modulator of acetylcholine receptor function, on airway responsiveness and allergen-induced responses in patients with mild asthma. Can Respir J. 2015 Jul-Aug;22(4):230-4.
• [20] Therapeutic advances in the treatment of nicotine addiction: present and future. Ther Adv Chronic Dis. 2010 May; 1(3): 95-106.
• [21] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.